Diana Do, MD

Expert panelists provide an overview of current unmet needs in wet AMD care and discuss the potential for improving clinical outcomes and treatment burden.

Key opinion leaders in ophthalmology comment on the potential role of alternative targets beyond VEGF-A including VEGF-C/VEGF-D and tyrosine kinase inhibitors.

A panel of expert ophthalmologists provides insight into emerging clinical trial data on new molecules, surgical implants, and gene therapy in wet AMD.

A panel of experts discusses nonexudative neovascular AMD and challenges associated with diagnostic imaging such as OCT-A and fluorescein angiography.

Key opinion leaders discuss factors to consider when selecting treatments in wet AMD including insurance considerations and degree of clinical response.

Panelists consider the theoretical systemic safety of anti-VEGF agents in wet AMD and discuss their role in the management of patients with risk factors.

Experts compare the safety and efficacy of agents currently available for wet AMD treatment and emphasize the importance of post-marketing surveillance.

Panelists give insight into the role of anti-VEGF therapy for wet AMD treatment and share personal experiences counseling patients on the goals of therapy.

Experts share best practices for managing the treatment burden of wet AMD including treat-and-extend, loading doses, monitoring, and hybrid telemedicine.

A panel of experts considers the impact of COVID-19 on wet AMD management and discusses the potential for telemedicine and home monitoring devices.

Key opinion leaders in ophthalmology provide an overview of age-related macular degeneration and comment on clinical recommendations for assessing symptoms.

Considerations in the treatment of diabetic retinopathy and diabetic macular edema.